Breast neoplasms Trials in Angers, France
Conditions / Breast neoplasms / Angers, France
Research into Breast neoplasms spans multiple therapeutic approaches and trial phases.
14 total trials for this combination
Showing top 10 of 14 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01572038 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer | COMPLETED | PHASE3 |
| NCT04895358 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00073528 | Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | COMPLETED | PHASE3 |
| NCT02258451 | Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer | COMPLETED | PHASE2 |
| NCT00038467 | Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer | COMPLETED | PHASE3 |
| NCT01125566 | LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | COMPLETED | PHASE3 |
| NCT02131064 | A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | COMPLETED | PHASE3 |
| NCT05386108 | Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | RECRUITING | PHASE1/PHASE2 |
| NCT00435409 | A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer | COMPLETED | PHASE3 |
| NCT03250676 | Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | COMPLETED | PHASE1/PHASE2 |